Investment In New Products: Looking Beyond The R&D Line

Johnson & Johnson and Roche lead the most recent Scrip 100 ranking for R&D spend, but a look beyond investment in internal development highlights a big year for Pfizer and Bristol Myer Squibb.

Look Out Cliff edge
• Source: Shutterstock

More from 2024

More from Outlook